Cite
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
MLA
Penson, Richard T., et al. “Bevacizumab for Advanced Cervical Cancer: Patient-Reported Outcomes of a Randomised, Phase 3 Trial (NRG Oncology-Gynecologic Oncology Group Protocol 240).” Lancet Oncology, vol. 16, no. 3, Mar. 2015, pp. 301–11. EBSCOhost, https://doi.org/10.1016/S1470-2045(15)70004-5.
APA
Penson, R. T., Huang, H. Q., Wenzel, L. B., Monk, B. J., Stockman, S., Long 3rd, H. J., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J. A., Leitao, M. M., Method, M., Michael, H., Tewari, K. S., & Long, H. J., 3rd. (2015). Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncology, 16(3), 301–311. https://doi.org/10.1016/S1470-2045(15)70004-5
Chicago
Penson, Richard T, Helen Q Huang, Lari B Wenzel, Bradley J Monk, Sharon Stockman, Harry J Long 3rd, Lois M Ramondetta, et al. 2015. “Bevacizumab for Advanced Cervical Cancer: Patient-Reported Outcomes of a Randomised, Phase 3 Trial (NRG Oncology-Gynecologic Oncology Group Protocol 240).” Lancet Oncology 16 (3): 301–11. doi:10.1016/S1470-2045(15)70004-5.